---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241963"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:26:01.080970+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill

## Summary
- Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).
- Loan amendment: Avenue converts $6M debt into 12.5M shares and warrants on same PIPE terms.
- Collaboration with Chugai: $10M upfront, up to $18M tech transfer, $57M development, $100M sales milestones, plus royalties.
- Samsara and Anomaly get board appointment rights if each holds ≥25% of its PIPE securities.
- Warrants exercisable five years post-stockholder approval; pre-funded warrants exercisable immediately.

## SEC filing metadata
- accession: 0001193125-25-241963
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312525241963/0001193125-25-241963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312525241963/d38236d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241963
- JSON: https://secwatch.observer/filing/0001193125-25-241963.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241963.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.